Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial
James O. Lindsay(Barts Health NHS Trust), John A. Snowden(Sheffield Teaching Hospitals NHS Foundation Trust), Jack Satsangi(Nuffield Orthopaedic Centre), Lizzie Swaby(King's College London), Sergio Rutella(Bambino Gesù Children's Hospital), Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Shahida Din(Western General Hospital), Uday Bannur C(Nottingham University Hospitals NHS Trust), Emily Turton(University of Sheffield), Richard Emsley(University of Manchester), Hannah Berntsson(University of Sheffield), A. Graham Pockley(Royal Hallamshire Hospital), Daniel Hind(University of Sheffield), Sreedhar Subramanian(University of Liverpool), Diana Papaioannou(University of Sheffield), Alan Lobo(Sheffield Teaching Hospitals NHS Foundation Trust), Miles Parkes(Cambridge University Hospitals NHS Foundation Trust), John G. Gribben(Queen Mary University of London), Gordon W. Moran(Nottingham University Hospitals NHS Trust), Yashwant R. Mahida(Nottingham University Hospitals NHS Trust), Jenny Byrne(Nottingham University Hospitals NHS Trust), Simon Travis(University of Oxford), Ben Uttenthal(Cambridge University Hospitals NHS Foundation Trust), Mike Bradburn(University of Sheffield), Benjamin Dickins(Nottingham Trent University), Gemma A. Foulds(John Radcliffe Hospital), Lauren Desoysa(University of Sheffield), Ellen Lee(Ford Motor Company (United States)), Christopher Clarke(Nottingham University Hospitals NHS Trust), Andrew Peniket(Oxford University Hospitals NHS Trust), C J Hawkey(NIHR Nottingham Digestive Diseases Biomedical Research Unit), Majid Kazmi, Amanda Loban(University of Sheffield)
Cited by 19
Related Papers
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
|Nature Genetics|2017|1.5k